$69.57
0.280.40%
At close: Apr 20, 5:00 PM EST
$69.57
N/A
After Hours: 4:00 PM EST
Halozyme Therapeutics Inc Stock Guidance
HALONASDAQ
Halozyme Therapeutics (HALO) last issued guidance on February 17, 2026 for fiscal year 2026. The company guided earnings per share in the range of $7.75 - $8.25, compared to a consensus EPS estimate of $7.38. Halozyme Therapeutics also guided revenue in the range of $1.71B - $1.81B for the period.
Compared to prior guidance, Halozyme Therapeutics maintained its EPS outlook from a previous range of $7.75 - $8.25. On the revenue side, the company maintained its revenue forecast from a prior range of $1.71B - $1.81B.
Halozyme Therapeutics has issued 25 guidance updates between May 10, 2022 and February 17, 2026. During this period, the company raised its outlook 14 times, reflecting management's growing confidence in business performance.
Latest Guidance Date
Feb 17, 2026
Guidance Period
Full Year 2026
EPS Guidance Range
$7.75 - $8.25
Revenue Guidance Range
$1.71B - $1.81B
Halozyme Therapeutics Guidance History
Review all historical guidance issued by Halozyme Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Halozyme Therapeutics (HALO)?
The most recent guidance for Halozyme Therapeutics (HALO) was reported on February 17, 2026 for the fiscal year 2026. The company provided earnings per share guidance in the range of $7.75 to $8.25, compared to the estimated EPS of $7.38. Additionally, Halozyme Therapeutics forecasted revenue between $1.71B and $1.81B for the period.
What EPS range did Halozyme Therapeutics (HALO) guide for?
Halozyme Therapeutics (HALO) guided EPS in the range of $7.75 to $8.25 for the fiscal year 2026. The consensus analyst EPS estimate is $7.38.
What revenue range did Halozyme Therapeutics (HALO) guide for?
Halozyme Therapeutics (HALO) guided revenue in the range of $1.71B to $1.81B for the fiscal year 2026.
Did Halozyme Therapeutics (HALO) raise or lower guidance?
Halozyme Therapeutics (HALO) maintained its EPS guidance from a prior range of $7.75 - $8.25 to $7.75 - $8.25 for the fiscal year 2026.
When did Halozyme Therapeutics (HALO) last issue guidance?
Halozyme Therapeutics (HALO) last issued guidance on February 17, 2026 for the fiscal year 2026.
